ASND
Ascendis PharmaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ASND Profile
Ascendis Pharma A/S
A leading, fully integrated biopharma company
Biological Technology
09/21/2006
01/28/2015
NASDAQ Stock Exchange
1,017
12-31
Depository Receipts (Ordinary Shares)
Tuborg Boulevard 12, DK-2900 Hellerup, Denmark
--
Ascendis Pharma A/s was established on September 21, 2006. The company is a clinical-stage biopharmaceutical company that uses its TransCon technology to develop a pipeline of optimal long-acting drug therapies to address significant unmet medical needs in a large market. The company is developing its lead product candidate, TransCon human growth hormone or growth hormone TransCon, once a week for the treatment of growth hormone deficiency and other diseases.
